Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
|Videos|March 1, 2017
Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Related to this article
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5